Oscient Pharmaceuticals Corp. (OSCIQ1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
1OO BEAVER ST WALTHAM, MA 02453

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Oscient Pharm operates as a commercial-stage biopharmaceutical company that focuses on expanding its business in the primary care physician marketplace in the U.S. The company's lead product is FACTIVE, a treatment for pneumonia and bronchitis.

View SEC Filings from OSCIQ1 instead.

View recent insider trading info

Funds Holding OSCIQ1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OSCIQ1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GLG PARTNERS LP

GLG PARTNERS LTD

GLG PARTNERS, INC.

GLG MARKET NEUTRAL FUND

  • 10% Owner
No longer subject to file 2009-05-21 0

BB BIOVENTURES L P

BAB BIO VENTURES LLP

BAB BIO VENTURES NV

MPM ASSET MANAGEMENT INVESTORS 1998 LLC

MPM BIOVENTURES I LP

MPM BIOVENTURES PARALLEL FUND L P

MPM BIO VENTURES I LLC

EVNIN LUKE

GADICKE ANSBERT

STEINMETZ MICHAEL

  • 10% Owner
4,222 2009-05-15 0

DELLACAMERA CAPITAL MANAGEMENT, LLC

  • 10% Owner
No longer subject to file 2009-05-13 0

AKANTHOS CAPITAL MANAGEMENT LLC

AKANTHOS ARBITRAGE MASTER FUND LP

  • 10% Owner
1,790,000 2008-11-25 0

AKANTHOS CAPITAL MANAGEMENT LLC

AKANTHOS ARBITRAGE MASTER FUND LP

MICHAEL KAO

  • 10% Owner
1,790,000 2008-11-25 0

GLICKMAN MARK A SVP, SALES & MARKETING

  • Officer
26,157 2008-07-28 0

RIEDEL NORBERT G

  • Director
1,340 2008-06-12 0

REARDON WILLIAM S

  • Director
2,553 2008-06-12 0

HENNESSEY ROBERT J

  • Director
6,958 2008-06-12 0

STONE DAVID K

  • Director
4,850 2008-06-12 0

PATOU GARY

  • Director
14,141 2008-06-12 0

LEONE JOHN R

  • Director
  • 10% Owner
1,389,789 2008-06-12 0

MATTSON WILLIAM R JR

  • Director
1,200 2008-06-12 0

BROWN GREGORY B

  • Director
1,200 2008-06-12 0

RAUSCHER STEVEN M CEO AND PRESIDENT

  • Officer
  • Director
67,210 2008-02-25 0

COLANGELO DOMINICK EVP CORPORATE DEV & OPERATIONS

  • Officer
46,469 2008-02-25 0

MAITRE PHILIPPE M SVP & CFO

  • Officer
43,825 2008-02-25 0

VISIUM ASSET MANAGEMENT, LP

JACOB GOTTLIEB

JG ASSET, LLC

  • 10% Owner
0 2007-09-14 0

VORIS JOHN E

  • Director
1,350 2007-06-07 0

FLAMENBAUM WALTER MD

  • Director
  • 10% Owner
1,390,539 2007-06-07 0

HIGHBRIDGE CAPITAL MANAGEMENT LLC

HIGHBRIDGE INTERNATIONAL LLC

SMITHFIELD FIDUCIARY LLC

DUBIN GLENN

SWIECA HENRY

  • 10% Owner
7,421 2007-04-26 0

PAUL ROYALTY FUND II L P

PAUL ROYALTY FUND HOLDINGS II

PAUL ROYALTY ASSOCIATES II, LP

PAUL ROYALTY MANAGEMENT, LLC

PAUL CAPITAL ADVISORS, LLC

  • 10% Owner
11,111,111 2006-08-18 0

KIRBY PAMELA J

  • Director
8,400 2006-06-08 0

SINGER DAVID B

  • Director
823,311 2006-06-07 0

COHEN STEPHEN SVP AND CFO

  • Officer
101,529 2006-05-22 0

EVNIN LUKE

  • Director
2,272,935 2006-01-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments